| US 7,501,113 B2 | ||
| Aerosol formulations and aerosol delivery of buprenorphine | ||
| Frank E. Blondino, Richmond, Va. (US); Justin Poklis, Chapel Hill, N.C. (US); and Matthew Baker, Richmond, Va. (US) | ||
| Assigned to Philip Morris USA Inc., Richmond, Va. (US) | ||
| Filed on Dec. 15, 2003, as Appl. No. 10/734,150. | ||
| Claims priority of provisional application 60/444622, filed on Feb. 04, 2003. | ||
| Prior Publication US 2004/0151670 A1, Aug. 05, 2004 | ||
| This patent is subject to a terminal disclaimer. | ||
| Int. Cl. A61K 9/12 (2006.01); A61M 16/00 (2006.01); A61M 16/12 (2006.01) | ||
| U.S. Cl. 424—45 [514/958; 128/200.14; 128/203.12; 128/203.16] | 11 Claims |
| 1. A method of generating an aerosol comprising:
supplying a liquid aerosol formulation to a capillary-sized flow passage,
heating the liquid aerosol formulation in the capillary-sized flow passage so as to volatilize a liquid component thereof
and form a vapor which exits from an outlet of the capillary-sized flow passage, and
contacting the vapor with a gaseous medium so as to form an aerosol,
wherein the liquid aerosol formulation includes at least one thermally stable active ingredient selected from the group consisting
of buprenorphine, pharmaceutically acceptable salts and esters thereof.
|